Induction of immunological memory response by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex in a mouse hepatocellular carcinoma model

Kwon,Sanghoon; Kim,Dongbum; Park,Byoung  Kwon; Wu,Guang; Park,Min  Chul; Ha,Yang-Wha; Kwon,Hyung-Joo; Lee,Younghee

doi:10.3892/or.2012.2130

Induction of immunological memory response by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex in a mouse hepatocellular carcinoma model

Authors:
- Sanghoon Kwon
- Dongbum Kim
- Byoung Kwon Park
- Guang Wu
- Min Chul Park
- Yang-Wha Ha
- Hyung-Joo Kwon
- Younghee Lee
View Affiliations

Affiliations: Center for Medical Science Research, College of Medicine, Hallym University, Gangwon, Republic of Korea, Department of Microbiology, College of Medicine, Hallym University, Gangwon, Republic of Korea, Department of Biochemistry, College of Natural Sciences, Chungbuk National University, Chungbuk, Republic of Korea
Published online on: November 9, 2012 https://doi.org/10.3892/or.2012.2130
Pages: 735-740

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The innovation of a peptide vaccine strategy may contribute to the development of efficacious and convenient cancer vaccines. Recently, we formulated an efficacious peptide vaccine without carriers using the natural phosphodiester bond CpG-DNA and a special liposome complex [Lipoplex(O)]. The peptide vaccine targeting a tumor antigen, transmembrane 4 superfamily member 5 protein (TM4SF5), was confirmed to have preventive and therapeutic effects in a mouse hepatocellular carcinoma (HCC) model. In this study, we demonstrated that the isotype-switched (IgM-IgD-) B cell population increased after immunization and that the functional memory response persisted for at least 70 days after the final immunization of mice. Delayed implantation of BNL-HCC cells significantly induced the peptide-specific IgG2a production in the immunized mice. Accordingly, tumor growth was inhibited and the survival rate increased. These results suggest that our peptide vaccine induces memory response, which is essential for cancer vaccine application.

View Figures

View References

1	Abbas A, Lichtman A and Pillai S: Cellular and Molecular Immunology. 6th edition. Saunders Elsevier; Philadelphia, PA: 2007
2	Aly HA: Cancer therapy and vaccination. J Immunol Methods. 382:1–23. 2012. View Article : Google Scholar
3	Hislop AD, Taylor GS, Sauce D and Rickinson AB: Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol. 25:587–617. 2007. View Article : Google Scholar : PubMed/NCBI
4	Finn OJ: Cancer immunology. N Engl J Med. 358:2704–2715. 2008. View Article : Google Scholar : PubMed/NCBI
5	Schreiber TH, Raez L, Rosenblatt JD and Podack ER: Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art. Semin Immunol. 22:105–112. 2010. View Article : Google Scholar : PubMed/NCBI
6	Bijker MS, Melief CJ, Offringa R and van der Burg SH: Design and development of synthetic peptide vaccines: past, present and future. Expert Rev Vaccines. 6:591–603. 2007. View Article : Google Scholar : PubMed/NCBI
7	Bode C, Zhao G, Steinhagen F, Kinjo T and Klinman DM: CpG DNA as a vaccine adjuvant. Expert Rev Vaccines. 10:499–511. 2011. View Article : Google Scholar : PubMed/NCBI
8	Klinman DM, Currie D, Gursel I and Verthelyi D: Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev. 199:201–216. 2004. View Article : Google Scholar : PubMed/NCBI
9	Krieg AM: CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 20:709–760. 2002. View Article : Google Scholar : PubMed/NCBI
10	Chu RS, Targoni OS, Krieg AM, Lehmann PV and Harding CV: CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med. 186:1623–1631. 1997. View Article : Google Scholar : PubMed/NCBI
11	Carson DA and Raz E: Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. J Exp Med. 186:1621–1622. 1997. View Article : Google Scholar : PubMed/NCBI
12	Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J and Krieg AM: CpG-DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol. 160:870–876. 1998.PubMed/NCBI
13	Kim D, Rhee JW, Kwon S, Sohn WJ, Lee Y, et al: Immunostimulation and anti-DNA antibody production by backbone modified CpG-DNA. Biochem Biophys Res Commun. 379:362–367. 2009. View Article : Google Scholar : PubMed/NCBI
14	Lipford GB, Sparwasser T, Zimmermann S, Heeg K and Wagner H: CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses. J Immunol. 165:1228–1235. 2000. View Article : Google Scholar : PubMed/NCBI
15	Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, et al: Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med. 10:187–192. 2004. View Article : Google Scholar : PubMed/NCBI
16	Deng GM, Nilsson IM, Verdrengh M, Collins LV and Tarkowski A: Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis. Nat Med. 5:702–705. 1999. View Article : Google Scholar : PubMed/NCBI
17	Lee KW, Jung J, Lee Y, Kim TY, Choi SY, et al: Immunostimulatory oligodeoxynucleotide isolated from genome wide screening of Mycobacterium bovis chromosomal DNA. Mol Immunol. 43:2107–2118. 2006. View Article : Google Scholar : PubMed/NCBI
18	Henriksen-Lacey M, Korsholm KS, Andersen P, Perrie Y and Christensen D: Liposomal vaccine delivery systems. Expert Opin Drug Deliv. 8:505–519. 2011. View Article : Google Scholar
19	Suzuki Y, Wakita D, Chamoto K, Narita Y, Tsuji T, et al: Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity. Cancer Res. 64:8754–8760. 2004. View Article : Google Scholar : PubMed/NCBI
20	Kim D, Kwon S, Rhee JW, Kim KD, Kim YE, et al: Production of antibodies with peptide-CpG-DNA-liposome complex without carriers. BMC Immunol. 12:292011. View Article : Google Scholar : PubMed/NCBI
21	Kim D, Kwon S, Ahn CS, Lee Y, Choi SY, Park J, Kwon HY and Kwon HJ: Adjuvant effect of liposome-encapsulated natural phosphodiester CpG-DNA. BMB Rep. 44:758–763. 2011. View Article : Google Scholar : PubMed/NCBI
22	Kim D, Kwon HJ and Lee Y: Activation of Toll-like receptor 9 and production of epitope specific antibody by liposome-encapsulated CpG-DNA. BMB Rep. 44:607–612. 2011. View Article : Google Scholar : PubMed/NCBI
23	Lee SA, Lee SY, Cho IH, Oh MA, Kang ES, et al: Tetraspanin TM4SF5 mediates loss of contact inhibition through epithelial-mesenchymal transition in human hepatocarcinoma. J Clin Invest. 118:1354–1366. 2008. View Article : Google Scholar : PubMed/NCBI
24	Kwon S, Kim D, Park BK, Cho S, Kim KD, Kim YE, Park CS, Ahn HJ, Seo JN, Choi KC, Kim DS, Lee Y and Kwon HJ: Prevention and therapy of hepatocellular carcinoma by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex without carriers. PLoS One. 7:e331212012. View Article : Google Scholar : PubMed/NCBI
25	Yoshiji H, Kuriyama S, Ways DK, Yoshii J and Miyamoto Y: Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res. 59:4413–4418. 1999.PubMed/NCBI
26	Yoshiji H, Kuriyama S, Kawata M, Yoshii J, Ikenaka Y, et al: The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res. 7:1073–1078. 2001.
27	Richard K, Pierce SK and Song W: The agonists of TLR4 and 9 are sufficient to activate memory B cells to differentiate into plasma cells in vitro but not in vivo. J Immunol. 181:1746–1752. 2008. View Article : Google Scholar : PubMed/NCBI
28	McHeyzer-Williams LJ and McHeyzer-Williams MG: Antigen-specific memory B cell development. Annu Rev Immunol. 23:487–513. 2005. View Article : Google Scholar : PubMed/NCBI
29	Hayakawa K, Ishii R, Yamasaki K, Kishimoto T and Hardy RR: Isolation of high-affinity memory B cells: phycoerythrin as a probe for antigen-binding cells. Proc Natl Acad Sci USA. 84:1379–1383. 1987. View Article : Google Scholar : PubMed/NCBI
30	Ben-Yedidia T and Arnon R: Epitope-based vaccine against influenza. Expert Rev Vaccines. 6:939–948. 2007. View Article : Google Scholar
31	Ben-Yedidia T and Arnon R: Design of peptide and polypeptide vaccines. Curr Opin Biotechnol. 8:442–448. 1997. View Article : Google Scholar
32	Müller-Pillasch F, Wallrapp C, Lacher U, Friess H, Büchler M, Adler G and Gress TM: Identification of a new tumour-associated antigen TM4SF5 and its expression in human cancer. Gene. 208:25–30. 1998.PubMed/NCBI
33	Lee SA, Ryu HW, Kim YM, Choi S, Lee MJ, et al: Blockade of four-transmembrane L6 family member 5 (TM4SF5)-mediated tumorigenicity in hepatocytes by a synthetic chalcone derivative. Hepatology. 49:1316–1325. 2009. View Article : Google Scholar : PubMed/NCBI
34	Lekishvili T, Fromm E, Mujoomdar M and Berditchevski F: The tumour-associated antigen L6 (L6-Ag) is recruited to the tetraspanin-enriched microdomains: implication for tumor cell motility. J Cell Sci. 121:685–694. 2008. View Article : Google Scholar : PubMed/NCBI
35	Plotkin SA: Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 47:401–409. 2008. View Article : Google Scholar : PubMed/NCBI
36	Galli G, Medini D, Borgogni E, Zedda L, Bardelli M, Malzone C, Nuti S, Tavarini S, Sammicheli C, Hilbert AK, Brauer V, Banzhoff A, Rappuoli R, Del Giudice G and Castellino F: Adjuvanted H5N1 vaccine induces early CD4⁺ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci USA. 106:3877–3882. 2009.PubMed/NCBI
37	Vieira P and Rajewsky K: Persistence of memory B cells in mice deprived of T cell help. Int Immunol. 2:487–494. 1990. View Article : Google Scholar : PubMed/NCBI
38	Cancro MP: The persistence of memory: a unique niche for IgG memory B cells. Proc Natl Acad Sci USA. 107:12737–12738. 2010. View Article : Google Scholar : PubMed/NCBI
39	Bernasconi NL, Onai N and Lanzavecchia A: A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood. 101:4500–4504. 2003. View Article : Google Scholar : PubMed/NCBI
40	Chiriva-Internati M, Yu Y, Mirandola L, Jenkins MR, Chapman C, Cannon M, Cobos E and Kast WM: Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. PLoS One. 5:e104712010. View Article : Google Scholar : PubMed/NCBI
41	Cerkovnik P, Novakovic BJ, Stegel V and Novakovic S: Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity. BMC Immunol. 11:452010. View Article : Google Scholar : PubMed/NCBI
42	Chikh G and Schutze-Redelmeier MP: Liposomal delivery of CTL epitopes to dendritic cells. Biosci Rep. 22:339–353. 2002. View Article : Google Scholar : PubMed/NCBI
43	Chang JS, Choi MJ, Cheong HS and Kim K: Development of Th1-mediated CD8⁺ effector T cells by vaccination with epitope peptides encapsulated in pH-sensitive liposomes. Vaccine. 19:3608–3614. 2001.PubMed/NCBI
44	Gursel I, Gursel M, Ishii KJ and Klinman DM: Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J Immunol. 167:3324–3328. 2001. View Article : Google Scholar : PubMed/NCBI